Janssen Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN PHARMS, and what generic alternatives to JANSSEN PHARMS drugs are available?
JANSSEN PHARMS has fifty-eight approved drugs.
There are twenty-nine US patents protecting JANSSEN PHARMS drugs.
There are seven hundred and thirteen patent family members on JANSSEN PHARMS drugs in sixty-five countries and one hundred and two supplementary protection certificates in eighteen countries.
Summary for Janssen Pharms
International Patents: | 713 |
US Patents: | 29 |
Tradenames: | 57 |
Ingredients: | 35 |
NDAs: | 58 |
Drugs and US Patents for Janssen Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Pharms | ULTRACET | acetaminophen; tramadol hydrochloride | TABLET;ORAL | 021123-001 | Aug 15, 2001 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-004 | Mar 18, 2021 | RX | Yes | No | 10,220,023 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-005 | Mar 18, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Janssen Pharms | PONVORY | ponesimod | TABLET;ORAL | 213498-003 | Mar 18, 2021 | RX | Yes | No | 10,220,023 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Pharms | INVOKAMET XR | canagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205879-004 | Sep 20, 2016 | RX | Yes | Yes | 8,513,202 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Janssen Pharms | RISPERDAL CONSTA | risperidone | INJECTABLE;INTRAMUSCULAR | 021346-003 | Oct 29, 2003 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Janssen Pharms | RISPERDAL | risperidone | TABLET, ORALLY DISINTEGRATING;ORAL | 021444-005 | Dec 23, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Janssen Pharms
Paragraph IV (Patent) Challenges for JANSSEN PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 25 mg, 100 mg and 200 mg | ➤ Subscribe | 2001-12-26 |
➤ Subscribe | Capsules | 15 mg and 25 mg | ➤ Subscribe | 2005-09-07 |
➤ Subscribe | Tablets | 10 mg, 15 mg, and 20 mg | ➤ Subscribe | 2015-07-01 |
➤ Subscribe | Tablets | 4 mg, 8 mg and 12 mg | ➤ Subscribe | 2005-02-28 |
➤ Subscribe | Orally Disintegrating Tablets | 3 mg and 4 mg | ➤ Subscribe | 2005-03-23 |
➤ Subscribe | Extended-release Tablets | 18 mg, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
➤ Subscribe | Tablets | 6.25 mg and 12.5 mg | ➤ Subscribe | 2005-12-08 |
➤ Subscribe | Extended-release Capsules | 8 mg | ➤ Subscribe | 2006-03-02 |
➤ Subscribe | Tablets | 100 mg and 300 mg | ➤ Subscribe | 2017-03-29 |
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2013-05-03 |
➤ Subscribe | Tablets | 50 mg | ➤ Subscribe | 2005-09-08 |
➤ Subscribe | Transdermal System | 0.15 mg/0.02 mg per 24 hours | ➤ Subscribe | 2007-03-22 |
➤ Subscribe | Oral Solution | 25 mg/mL | ➤ Subscribe | 2009-07-30 |
➤ Subscribe | Orally Disintegrating Tablets | 0.25 mg | ➤ Subscribe | 2005-04-11 |
➤ Subscribe | Extended-release Injectable Suspension | 39 mg/0.25 mL,78 mg/0.5 mL,117 mg/0.75 mL,156 mg/mL and234 mg/1.5 mL | ➤ Subscribe | 2017-11-21 |
➤ Subscribe | Extended-release Tablets | 18 mg*, 27 mg, 36 mg and 54 mg | ➤ Subscribe | 2005-07-19 |
➤ Subscribe | Tablets | 50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg | ➤ Subscribe | 2017-03-29 |
➤ Subscribe | Extended-release Capsules | 16 mg and 24 mg | ➤ Subscribe | 2006-03-11 |
International Patents for Janssen Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 4496174 | ⤷ Try a Trial |
Iceland | 8443 | ⤷ Try a Trial |
Brazil | PI0413232 | ⤷ Try a Trial |
Portugal | 2234617 | ⤷ Try a Trial |
Norway | 20074356 | ⤷ Try a Trial |
European Patent Office | 4005555 | ⤷ Try a Trial |
China | 102883726 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Janssen Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1651658 | 164 1-2014 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: KANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/008 20131115 |
1651658 | PA2014008,C1651658 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013- 11-15 EU/1/13/884/005 - EU/1/13/884/008 20131115 |
1769785 | C300521 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006 |
2805723 | LUC00064 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824 |
1651658 | CA 2014 00024 | Denmark | ⤷ Try a Trial | PRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115 |
1429780 | 132013902137451 | Italy | ⤷ Try a Trial | PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106 |
1453521 | 300814 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.